Search details
1.
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
; 397(10271): 281-292, 2021 01 23.
Article
in English
| MEDLINE | ID: mdl-33485453
2.
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Gynecol Oncol
; 167(3): 404-413, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36273926
3.
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
Br J Cancer
; 125(12): 1666-1676, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34663950
4.
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
Int J Gynecol Cancer
; 31(7): 949-958, 2021 07.
Article
in English
| MEDLINE | ID: mdl-34103386
5.
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(5): 710-722, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32359490
6.
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
Gynecol Oncol
; 159(1): 101-111, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32861537
7.
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 390(10106): 1949-1961, 2017 Oct 28.
Article
in English
| MEDLINE | ID: mdl-28916367
8.
A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies.
J Transl Med
; 14: 83, 2016 Mar 31.
Article
in English
| MEDLINE | ID: mdl-27036206
9.
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.
Gynecol Oncol
; 137(2): 216-22, 2015 May.
Article
in English
| MEDLINE | ID: mdl-25769658
10.
Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection.
Int J Cancer
; 131(3): E204-15, 2012 Aug 01.
Article
in English
| MEDLINE | ID: mdl-22173567
11.
The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells.
Cancer Cell Int
; 11(1): 29, 2011 Aug 19.
Article
in English
| MEDLINE | ID: mdl-21854619
12.
Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
Cancer Med
; 10(9): 3045-3058, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33811746
13.
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.
Cancer Med
; 10(20): 7162-7173, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34549539
14.
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer.
Clin Cancer Res
; 26(18): 4767-4776, 2020 09 15.
Article
in English
| MEDLINE | ID: mdl-32611648
15.
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
J Clin Oncol
; 38(30): 3494-3505, 2020 10 20.
Article
in English
| MEDLINE | ID: mdl-32840418
16.
A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium.
Clin Cancer Res
; 24(24): 6168-6174, 2018 12 15.
Article
in English
| MEDLINE | ID: mdl-30108107
17.
Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3.
Clin Cancer Res
; 23(15): 4501-4510, 2017 Aug 01.
Article
in English
| MEDLINE | ID: mdl-28377483
18.
Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors.
Mol Cancer Ther
; 13(11): 2559-71, 2014 Nov.
Article
in English
| MEDLINE | ID: mdl-25189541
19.
Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer.
Cancer Genet
; 204(10): 525-35, 2011 Oct.
Article
in English
| MEDLINE | ID: mdl-22137482
20.
BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer.
J Oncol
; 2010: 891059, 2010.
Article
in English
| MEDLINE | ID: mdl-20182637